AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32870242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood transplantation
Number of subjects: 368
Study 32870242 — intervention group
Group type: COMPARATOR
Intervention: Haploidentical transplantation
Number of subjects: 368
Study 36442824 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG Belt system (EBS) for CRT implantation and programming
Number of subjects: 408
Study 36442824 — intervention group
Group type: COMPARATOR
Intervention: Standard CRT care
Number of subjects: 408
Study 33880021 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF stretching combined with aerobic training (10-minute PNF stretching 3 times every training day for 6 weeks)
Number of subjects: 55
Study 33880021 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (30 min on a treadmill, 5 days per week for 6 weeks)
Number of subjects: 55
Study 32151570 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced follow-up protocol
Number of subjects: 162
Study 32151570 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up protocol
Number of subjects: 162
Study 35134817 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-HCTZ
Number of subjects: 635
Study 35134817 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-Perindopril
Number of subjects: 635
Study 35134817 — intervention group
Group type: COMPARATOR
Intervention: Perindopril-HCTZ
Number of subjects: 635
Study 35134817 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory BP monitoring
Number of subjects: 635
Study 34950225 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training (PT)
Number of subjects: 168
Study 34950225 — intervention group
Group type: COMPARATOR
Intervention: Parent education (PE)
Number of subjects: 168
Study 35853995 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowdsourced HBV/HCV promotion materials through social media
Number of subjects: 750
Study 35853995 — intervention group
Group type: COMPARATOR
Intervention: Facility-based care without promotional materials
Number of subjects: 750
Study 32316070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) Q4W
Number of subjects: 171
Study 32316070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 35017261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette packs with background colour and capsule image
Number of subjects: 2450
Study 35017261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette packs named 'Tropical Burst'
Number of subjects: 2450
Study 35017261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette packs named 'Arctic Air'
Number of subjects: 2450
Study 35017261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette packs displaying a flavour name, background colour or capsule image
Number of subjects: 2450
Study 34125811 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal educational intervention (five group and three individual sessions on feeding practices)
Number of subjects: 60
Study 34125811 — intervention group
Group type: COMPARATOR
Intervention: Routine care (at least three prenatal consultations)
Number of subjects: 60
Study 32323560 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention for 12 weeks
Number of subjects: 24
Study 32323560 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 24
Study 34826166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 408
Study 34826166 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 408
Study 32543461 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel City®3.0 virtual simulation program
Number of subjects: 0
Study 32543461 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical placements (agencies or geographical neighbourhoods)
Number of subjects: 0
Study 616451442 — intervention group
Group type: EXPERIMENTAL
Intervention: dSM265
Number of subjects: 0
Study 616451442 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35968208 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotic (Pedilact) - 5 drops containing Lactobacillus reuteri and simethicone (20 mg twice daily) for 4 weeks
Number of subjects: 76
Study 35968208 — intervention group
Group type: COMPARATOR
Intervention: Placebo with simethicone for 4 weeks
Number of subjects: 76
Study 35099283 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy (BIS)
Number of subjects: 1200
Study 35099283 — intervention group
Group type: COMPARATOR
Intervention: Tape measurement (TM)
Number of subjects: 1200
Study 35099283 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 1200
Study 32604427 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful ultrasound-accelerated catheter-directed thrombolysis (UACDT)
Number of subjects: 152
Study 32604427 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 152
Study 32604427 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful UACDT
Number of subjects: 152
Study 35075138 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine chemotherapy alone or in combination with bevacizumab (± mitomycin C)
Number of subjects: 325
Study 33602996 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30 plus metformin
Number of subjects: 2
Study 33602996 — intervention group
Group type: COMPARATOR
Intervention: BIAsp 30
Number of subjects: 2
Study 34552008 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracyclines plus ifosfamide
Number of subjects: 231
Study 34552008 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus palifosfamide with MRP-1 inhibitors (nilotinib or avapritinib)
Number of subjects: 231
Study 34552008 — intervention group
Group type: COMPARATOR
Intervention: MRP-1 inhibitors (nilotinib, ripretinib, selumetinib, avapritinib)
Number of subjects: 231
Study 36389149 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting 80-day survival
Number of subjects: 331
Study 35110894 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided PECS I (0.2 ml/kg) and PECS II (0.4 ml/kg) block, post-induction with 0.25% levobupivacaine, maximum dose of 2 mg/kg.
Number of subjects: 60
Study 35110894 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided PECS I and II block
Number of subjects: 60
Study 35110894 — intervention group
Group type: COMPARATOR
Intervention: No block, only general anesthesia
Number of subjects: 60
Study 32278103 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased abdominal pressure using a 3000 ml bag of normal saline (NS)
Number of subjects: 0
Study 32278103 — intervention group
Group type: COMPARATOR
Intervention: No special treatment (Control group)
Number of subjects: 0
Study 32278103 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 34997248 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer-based navigation (ABN)
Number of subjects: 50
Study 34997248 — intervention group
Group type: COMPARATOR
Intervention: Computer-assisted navigation (CAN)
Number of subjects: 50
Study 35341689 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel CAR-T therapy
Number of subjects: 0
Study 32545026 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium in Multimicronutrient (MMN)
Number of subjects: 32
Study 32545026 — intervention group
Group type: COMPARATOR
Intervention: Iron and Folic Acid (IFA)
Number of subjects: 32
Study 35869526 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir plus nitazoxanide
Number of subjects: 0
Study 35869526 — intervention group
Group type: COMPARATOR
Intervention: Favipiravir plus nitazoxanide placebo
Number of subjects: 0
Study 33764470 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDi® robot intervention with standard care (SC) and Ametop©
Number of subjects: 137
Study 33764470 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC) with Ametop© only
Number of subjects: 137
Study 33764470 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDi® robot intervention
Number of subjects: 137
Study 32251038 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi intervention
Number of subjects: 17
Study 34489296 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of appropriate patients for deprescribing
Number of subjects: 50
Study 34489296 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 50
Study 34489296 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners (GP) education
Number of subjects: 50
Study 34489296 — intervention group
Group type: EXPERIMENTAL
Intervention: Development and use of a tapering schedule
Number of subjects: 50
Study 34489296 — intervention group
Group type: EXPERIMENTAL
Intervention: Engage practice staff in education and appropriate identification of patients
Number of subjects: 50
Study 34489296 — intervention group
Group type: EXPERIMENTAL
Intervention: Provide feedback to staff about deprescribing occurrences within the practice
Number of subjects: 50
Study 32492138 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/d of resveratrol (n = 20)
Number of subjects: 41
Study 32492138 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 21)
Number of subjects: 41
Study 33541227 — intervention group
Group type: EXPERIMENTAL
Intervention: National Death Index (NDI) for HIV deaths
Number of subjects: 50
Study 33541227 — intervention group
Group type: EXPERIMENTAL
Intervention: National Death Index (NDI) for non–AIDS‐related infectious diseases
Number of subjects: 50
Study 33541227 — intervention group
Group type: EXPERIMENTAL
Intervention: National Death Index (NDI) for non–AIDS‐related cancers
Number of subjects: 50
Study 33541227 — intervention group
Group type: EXPERIMENTAL
Intervention: National Death Index (NDI) for substance abuse
Number of subjects: 50
Study 33541227 — intervention group
Group type: EXPERIMENTAL
Intervention: National Death Index (NDI) for heart disease
Number of subjects: 50
Study 33541227 — intervention group
Group type: EXPERIMENTAL
Intervention: National Death Index (NDI) for hepatitis B/C
Number of subjects: 50
Study 33541227 — intervention group
Group type: EXPERIMENTAL
Intervention: National Death Index (NDI) for mental illness
Number of subjects: 50
Study 33541227 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between expert review and NDI for HIV deaths
Number of subjects: 50
Study 33541227 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between expert review and NDI for heart disease
Number of subjects: 50
Study 33541227 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between expert review and NDI for hepatitis B/C
Number of subjects: 50
Study 33541227 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between expert review and NDI for non–AIDS‐related infectious diseases
Number of subjects: 50
Study 33541227 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between expert review and NDI for non–AIDS‐related cancers
Number of subjects: 50
Study 33248530 — intervention group
Group type: EXPERIMENTAL
Intervention: IPR enhanced with youth- and parent-directed online Single-Session Interventions (SSIs) designed to reduce youths’ internalizing symptoms and improve parents’ mental health treatment expectancies.
Number of subjects: 246
Study 33248530 — intervention group
Group type: COMPARATOR
Intervention: Information, Psychoeducation, and Referral (IPR; ie, usual care)
Number of subjects: 246
Study 35334836 — intervention group
Group type: EXPERIMENTAL
Intervention: Three eggs per day for 4 weeks (choline equivalent of 400 mg/day)
Number of subjects: 23
Study 35334836 — intervention group
Group type: COMPARATOR
Intervention: Choline bitartrate (CB) supplement for 4 weeks (choline equivalent of 400 mg/day)
Number of subjects: 23
Study 32319963 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based self-monitoring (Lose it!)
Number of subjects: 36
Study 32319963 — intervention group
Group type: COMPARATOR
Intervention: Food journal self-monitoring (paper diaries)
Number of subjects: 36
Study 32346709 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed turbine minimally invasive surgery combined with immediate implantation
Number of subjects: 80
Study 32346709 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgery combined with immediate implantation
Number of subjects: 80
Study 33687312 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing care program based on the Theory of Human Caring (THC) alongside routine nursing care for five sessions
Number of subjects: 52
Study 33687312 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 52
Study 32936010 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg/day) combined with oral contraceptives (Desogestrel and Ethinylestradiol Tablets)
Number of subjects: 820
Study 32936010 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives (Desogestrel and Ethinylestradiol Tablets) alone
Number of subjects: 820
Study 34705283 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab (Isa) 10 mg/kg weekly for 4 weeks then every 2 weeks (QW-Q2W) in combination with pomalidomide/dexamethasone (Pd)
Number of subjects: 256
Study 34705283 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to a monthly dosing regimen of Isatuximab after 6 months
Number of subjects: 256
Study 34705283 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab (Isa) 10 mg/kg QW-Q2W regimen
Number of subjects: 256
Study 34705283 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with good prognostic characteristics and stable, very good partial response
Number of subjects: 256
Study 32673309 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher between-day variability in sleep onset
Number of subjects: 967
Study 32673309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep onset between 19:00 and 22:00
Number of subjects: 967
Study 32673309 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher between-day variability in sleep duration
Number of subjects: 967
Study 35866676 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash with Sambucus williamsii var. coreana extract (1x/day for 30 s for 1 day or 5 days)
Number of subjects: 77
Study 35866676 — intervention group
Group type: COMPARATOR
Intervention: Saline gargle (1x/day for 30 s)
Number of subjects: 77
Study 35866676 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash with Sambucus williamsii var. coreana extract (5 days treatment)
Number of subjects: 77
Study 33646464 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 0
Study 33646464 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy of physician’s choice
Number of subjects: 0
Study 32516810 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 40
Study 32516810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 33215715 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher quality caregiving in adolescence
Number of subjects: 0
Study 33389399 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC-oriented personalized adjuvant therapy (experimental group, n = 68)
Number of subjects: 128
Study 33389399 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 128
Study 36334308 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cognitively engaging movement games (20-min)
Number of subjects: 75
Study 36334308 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cognitively engaging movement games (40-min)
Number of subjects: 75
Study 36334308 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 34330261 — intervention group
Group type: EXPERIMENTAL
Intervention: kNN models using learned patient similarity
Number of subjects: 30
Study 34330261 — intervention group
Group type: COMPARATOR
Intervention: kNN models using Euclidean distance
Number of subjects: 30
Study 34330261 — intervention group
Group type: EXPERIMENTAL
Intervention: kNN models using learned patient similarity to identify top k nearest neighbors
Number of subjects: 30
Study 34330261 — intervention group
Group type: COMPARATOR
Intervention: Reference models
Number of subjects: 30
Study 36630863 — intervention group
Group type: COMPARATOR
Intervention: High-frequency DBS (130 Hz)
Number of subjects: 14
Study 36630863 — intervention group
Group type: COMPARATOR
Intervention: Mid-frequency DBS (60 Hz)
Number of subjects: 14
Study 36630863 — intervention group
Group type: COMPARATOR
Intervention: DBS off
Number of subjects: 14
Study 36630863 — intervention group
Group type: COMPARATOR
Intervention: Both 60 Hz and 130 Hz DBS
Number of subjects: 14
Study 34251664 — intervention group
Group type: EXPERIMENTAL
Intervention: iView Video Laryngoscope (VL)
Number of subjects: 32
Study 34251664 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 32
Study 35613527 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive behavior toward an automated vehicle (AV)
Number of subjects: 956
Study 35613527 — intervention group
Group type: COMPARATOR
Intervention: Aggressive behavior toward a human driver
Number of subjects: 956
Study 35613527 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim identity salience (high)
Number of subjects: 956
Study 35613527 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim identity salience (low)
Number of subjects: 956
Study 33669400 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plan with potentially beneficial foods for intestinal permeability (IP) in IBD patients (n = 14)
Number of subjects: 53
Study 33669400 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plan with potentially beneficial foods for intestinal permeability (IP) in control participants without disease (n = 14)
Number of subjects: 53
Study 33669400 — intervention group
Group type: COMPARATOR
Intervention: No intervention in IBD patients (n = 11)
Number of subjects: 53
Study 33669400 — intervention group
Group type: COMPARATOR
Intervention: No intervention in control participants without disease (n = 14)
Number of subjects: 53
Study 32134035 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid etching
Number of subjects: 60
Study 32134035 — intervention group
Group type: EXPERIMENTAL
Intervention: Er, Cr: YSGG laser irradiation at 3W
Number of subjects: 60
Study 32134035 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surface treatment)
Number of subjects: 60
Study 32134035 — intervention group
Group type: EXPERIMENTAL
Intervention: 1W Er, Cr: YSGG laser irradiation
Number of subjects: 60
Study 32134035 — intervention group
Group type: EXPERIMENTAL
Intervention: 2W Er, Cr: YSGG laser irradiation
Number of subjects: 60
Study 32134035 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.6% hydrofluoric acid etching
Number of subjects: 60
Study 33840312 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling for a Healthy Diet
Number of subjects: 120
Study 33840312 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Counseling
Number of subjects: 120
Study 33840312 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest observed MCAP Score
Number of subjects: 120
Study 33840312 — intervention group
Group type: EXPERIMENTAL
Intervention: MCAP Score correlation
Number of subjects: 120
Study 33840312 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvements in MCAP Score
Number of subjects: 120
Study 33373276 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAMSA‐Bu
Number of subjects: 244
Study 33373276 — intervention group
Group type: COMPARATOR
Intervention: Control (fludarabine‐based RIC regimen)
Number of subjects: 244
Study 35623869 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Carnitine (3000 mg/day) for 7 days
Number of subjects: 54
Study 35623869 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 54
Study 33258531 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage spinal cord stimulation (SCS) procedure (no screening trial)
Number of subjects: 31
Study 33258531 — intervention group
Group type: COMPARATOR
Intervention: Two-stage spinal cord stimulation (SCS) procedure (with screening trial)
Number of subjects: 31
Study 33822328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 397
Study 33822328 — intervention group
Group type: COMPARATOR
Intervention: Ramucirumab
Number of subjects: 397
Study 33594771 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant durvalumab during chemo/radiation therapy
Number of subjects: 0
Study 33594771 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy during chemo/radiation therapy
Number of subjects: 0
Study 32724912 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI)
Number of subjects: 0
Study 32724912 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 33850272 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release isosorbide mononitrate (40–60 mg)
Number of subjects: 58
Study 33850272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 34787298 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip training (IHT) performed three times per week (4 x 2 minutes at 30% of maximal voluntary contraction, one-minute rest between bouts, alternating the hands)
Number of subjects: 63
Study 34787298 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 63
Study 34787298 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip training (IHT)
Number of subjects: 63
Study 32233338 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (3.0 mg) plus lifestyle therapy
Number of subjects: 251
Study 32233338 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus lifestyle therapy
Number of subjects: 251
Study 34505234 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback messages indicating membership in an elite group of 'Top Performers' or actionable recommendations for 'Not Top Performers'
Number of subjects: 214
Study 34505234 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract)
Number of subjects: 214
Study 34879493 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray (10%)
Number of subjects: 67
Study 34879493 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 67
Study 36059410 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative multidisciplinary team nursing care based on the WeChat platform (experimental group)
Number of subjects: 56